| Literature DB >> 27486337 |
Xiaofei Lu1, Lingling Duan2, Hongqin Xie3, Xiaoxia Lu4, Daolin Lu5, Daopeng Lu6, Nan Jiang7, Yuxin Chen8.
Abstract
OBJECTIVE: Adenocarcinoma of esophagogastric junction (AEG) is a lethal malignancy featured with early metastasis, poor prognosis, and few treatment options. Matrix metalloproteinase (MMP) and metalloproteinase suppressor (TIMP) have been considered to be associated with cancer invasion and metastasis. In our study, we evaluated expressions of MMP-9, MMP-2, TIMP-1, and TIMP-2 in AEG and their correlation with clinicopathological parameters and the overall survival rate.Entities:
Keywords: MMP-2; MMP-9; TIMP-1; TIMP-2; adenocarcinoma of esophagogastric junction; metastasis; prognosis
Year: 2016 PMID: 27486337 PMCID: PMC4958364 DOI: 10.2147/OTT.S99580
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Representative cases of IHC staining for MMP-2, MMP-9, TIMP-1, and TIMP-2 of AEG.
Notes: (A and B) Case negative for MMP-2 and MMP-9 for IHC staining; (C and D) case negative for TIMP-1 and TIMP-2 for IHC staining; (E and F) strong membrane and cytoplasm staining of MMP-2 and MMP-9; (G and H) strong expression of TIMP-1 and TIMP-2 in the cytoplasm. Magnification ×200; Scale bar =50 μm.
Abbreviations: IHC, immunohistochemistry; MMP, matrix metalloproteinase; AEG, adenocarcinoma of esophagogastric junction.
Association of expression of MMP-9, MMP-2, TIMP-1, and TIMP-2 with clinicopathological parameters in AEG
| Parameters | N | MMP-9 positive
| MMP-2 positive
| TIMP-1 positive
| TIMP-2 positive
| ||||
|---|---|---|---|---|---|---|---|---|---|
| (%) | (%) | (%) | (%) | ||||||
| Age (years) | |||||||||
| <60 | 50 | 34 (68.0) | 0.140 | 26 (52.0) | 0.951 | 32 (64.0) | 0.243 | 41 (58.6) | 0.470 |
| ≥60 | 70 | 37 (52.9) | 36 (51.4) | 52 (74.3) | 32 (56.1) | ||||
| Sex | |||||||||
| Male | 63 | 38 (60.3) | 0.787 | 33 (52.4) | 0.822 | 40 (63.5) | 0.115 | 32 (55.2) | 0.588 |
| Female | 57 | 33 (57.9) | 29 (50.9) | 44 (77.2) | 24 (49.0) | ||||
| Tumor size (cm) | |||||||||
| <5 | 62 | 40 (64.5) | 0.218 | 30 (48.4) | 0.457 | 42 (67.7) | 0.691 | 0.800 | |
| ≥5 | 58 | 21 (53.4) | 32 (55.2) | 42 (72.4) | |||||
| Well | 23 | 7 (30.4) | 10 (43.5) | 17 (73.9) | |||||
| Depth of invasion | |||||||||
| Poor | 49 | 36 | 0.800 | 25 (51.0) | 0.457 | 28 (57.1) | 0.011 | 13 (39.4) | 0.143 |
| T1–T2 | 58 | 35 (60.3) | 32 (55.2) | 47 (81.0) | |||||
| T3–T4 | 62 | 36 (58.1) | 30 (48.4) | 37 (59.7) | 37 (59.7) | ||||
| Lymph node metastasis | |||||||||
| Positive | 74 | 50 (67.6) | 0.018 | 36 (48.6) | 0.401 | 57 (77.0) | 0.041 | 39 (52.7) | 0.955 |
| Negative | 46 | 21 (45.7) | 26 (56.5) | 27 (58.7) | 24 (52.2) | ||||
| UICC stage | |||||||||
| I+II | 59 | 28 (47.5) | 0.010 | 29 (49.2) | 0.588 | 48 (81.4) | 0.010 | 26 (44.1) | |
| III+IV | 61 | 43 (70.5) | 33 (54.1) | 36 (59.0) | 37 (60.7) | ||||
| Adjuvant chemotherapy | |||||||||
| Yes | 89 | 55 (61.8) | 0.320 | 50 (56.2) | 0.142 | 65 (73.0) | 0.258 | 46 (51.7) | 0.836 |
| No | 31 | 16 (51.6) | 12 (38.7) | 19 (61.3) | 17 (54.8) | ||||
Note:
Chi-square test, difference with P<0.05.
Abbreviations: MMP, matrix metalloproteinase; AEG, adenocarcinoma of esophagogastric junction; T, tumor (TNM staging system); TIMP, tissue inhibitor of metalloproteinase; UICC, Union for International Cancer Control.
Univariate analysis of overall survival in AEG
| Parameters | Category | No of events (%) | Median survival time (months) | 95% confidence interval | |
|---|---|---|---|---|---|
| Depth of invasion | T1+T2 | 19 (32.8) | 28 | 24.3–36.5 | 0.024 |
| T3+T4 | 33 (53.2) | 20 | 19.5–36.1 | ||
| Lymph node metastasis | Negative | 17 (36.9) | 40 | 21.0–58.6 | 0.001 |
| Positive | 35 (47.3) | 30 | 17.0–34.3 | ||
| TIMP-1 | Negative | 20 (55.6) | 29 | 25.6–40.1 | 0.040 |
| Positive | 32 (38.1) | 33 | 30.8–40.4 | ||
| MMP-9 | Negative | 36 (50.7) | 41 | 30.6–43.3 | 0.037 |
| Positive | 16 (32.7) | 22 | 13.4–31.7 | ||
| MMP-9+/TIMP-1- | Yes | 21 (65.6) | 18 | 14.2–30.5 | 0.001 |
| No | 31 (35.2) | 35 | 28.1–47.6 | ||
| Adjuvant chemotherapy | No | 15 (48.4) | 26 | 22.8–34.5 | 0.050 |
| Yes | 37 (41.5) | 31 | 29.6–40.2 |
Abbreviations: AEG, adenocarcinoma of esophagogastric junction; MMP-9, matrix metalloproteinase 9; T, tumor (TNM staging system); TIMP, tissue inhibitor of metalloproteinase.
Figure 2Survival curves stratified by MMP-9 and TIMP-1 in AEG (Kaplan–Meier method).
Notes: Univariate analysis of MMP-9 and TIMP-1 in AEG is shown in (A and B), respectively. (C) The outcome of MMP-9-positive and TIMP-1-negative phenotype was significantly worse than other combinations of MMP-9 and TIMP-1.
Abbreviations: MMP-9, matrix metalloproteinase 9; AEG, adenocarcinoma of esophagogastric junction.
Multivariate analysis of overall survival in AEG
| Parameters | Category | HR | 95% CI | |
|---|---|---|---|---|
| N stage | Negative | 1 | ||
| Positive | 2.337 | 2.024–4.166 | 0.008 | |
| T stage | I+II | 1 | ||
| III+IV | 1.987 | 1.651–2.304 | 0.035 | |
| MMP-9+/TIMP-1- | Others | 1 | ||
| Positive | 3.014 | 2.432–3.237 | 0.002 |
Abbreviations: HR, hazard ratio; CI, confidence interval; MMP-9, matrix metalloproteinase 9.